An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study

[1]  Yi-long Wu,et al.  Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial. , 2021 .

[2]  W. Curran,et al.  Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis. , 2020, The oncologist.

[3]  F. McDonald,et al.  International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy? , 2020, ERJ Open Research.

[4]  Ming-Ting Wu,et al.  Differences in lung cancer characteristics and mortality rate between screened and non-screened cohorts , 2019, Scientific Reports.

[5]  Ying Cheng,et al.  Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. , 2019, The New England journal of medicine.

[6]  D. de Ruysscher,et al.  Interdisciplinary multimodality management of stage III nonsmall cell lung cancer , 2019, European Respiratory Review.

[7]  T. Hsia,et al.  Comparative effectiveness of concurrent chemoradiotherapy versus EGFR‐tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR , 2018, Thoracic cancer.

[8]  B. Besse,et al.  Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? , 2018, Nature Reviews Clinical Oncology.

[9]  B. Nemesure,et al.  Survival Outcomes Among Lung Cancer Patients Treated Using a Multidisciplinary Team Approach , 2018, Clinical lung cancer.

[10]  J. Ahn,et al.  EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy , 2018, Cancer research and treatment : official journal of Korean Cancer Association.

[11]  Xiangdong Zhou,et al.  Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Arnaud Boyer,et al.  Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. , 2018, Journal of thoracic disease.

[13]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[14]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[15]  K. Hayakawa,et al.  Evaluation of concurrent chemoradiotherapy for locally advanced NSCLC according to EGFR mutation status. , 2017, Oncology letters.

[16]  V. Gebski,et al.  Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival , 2017, Journal of the National Cancer Institute.

[17]  V. Gebski,et al.  Checkpoint Inhibitors in Metastatic EGFR‐Mutated Non–Small Cell Lung Cancer—A Meta‐Analysis , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  R. Califf,et al.  Real-World Evidence - What Is It and What Can It Tell Us? , 2016, The New England journal of medicine.

[19]  D. de Ruysscher,et al.  The Optimal Local Treatment of Stage IIIA-N2 NSCLC: Is the Issue Finally Settled? , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  Y. Yatabe,et al.  EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  K. Jöckel,et al.  Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  F. Song,et al.  Outcome of surgery versus radiotherapy after induction treatment in patients with N2 disease: systematic review and meta-analysis of randomised trials , 2015, Thorax.

[24]  L. Sequist,et al.  Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. , 2015, The Lancet. Oncology.

[25]  Masahiro Endo,et al.  The Impact of Clinical Outcomes According to EGFR Mutation Status in Patients with Locally Advanced Lung Adenocarcinoma Who Recieved Concurrent Chemoradiotherapy , 2014, American journal of clinical oncology.

[26]  D. de Ruysscher,et al.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  Ching-Yuan Cheng,et al.  Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  Jose Belderbos,et al.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  V. Rusch,et al.  Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial , 2009, The Lancet.

[30]  P. Lambin,et al.  Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[31]  G. Giaccone,et al.  Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. , 2007, Journal of the National Cancer Institute.

[32]  J. Pignon,et al.  Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  D. Ettinger,et al.  Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group. , 2002, International journal of radiation oncology, biology, physics.